Chemo and RT Before Surgery Boosts Pancreatic Cancer Survival Chemo and RT Before Surgery Boosts Pancreatic Cancer Survival
Long-term results from the Dutch PREOPANC trial confirm that neoadjuvant chemoradiotherapy conveys a survival advantage to patients with resectable and borderline resectable pancreatic cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Netherlands Health | Pancreas | Pancreatic Cancer